GW Pharmaceuticals PLC- ADR


Piper Jaffray Reiterates Upbeat View on GW Pharmaceuticals PLC- ADR Following NYU Epilepsy Treatment Course

In a research report published today, Piper Jaffray analyst Joshua Schimmer offered some favorable commentary on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) after attending a one-day course at …

Stock Update (NASDAQ:GWPH): GW Pharmaceuticals PLC- ADR Announces the Closing of U.S. Public Offering

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, …

Stock Update (NASDAQ:GWPH): GW Pharmaceuticals PLC- ADR Announces Pricing of U.S. Public Offering of ADSs Raising $179.2 Million

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced …

Piper Jaffray Reiterates Overweight on GW Pharmaceuticals; Here’s Why

In a research report published today, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) with a price …

Stock Update (NASDAQ:GWPH): GW Pharmaceuticals Notes New Epidiolex(R) Data Released by the American Academy of Neurology

GW Pharmaceuticals PLC- ADR (Nasdaq:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today noted …

Stock Update (NASDAQ:GWPH): GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome

GW Pharmaceuticals PLC- ADR (Nasdaq:GWPH) (AIM:GWP), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts